TOP TEN perturbations for 1360_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1360_at
Selected probe(set): 205071_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1360_at (205071_x_at) across 6673 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-6.01058
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-4.3323126
Number of Samples:13 / 2
Experimental ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-4.2561703
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinoma, NOS of the ovary (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-4.013715
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-3.2661247
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

precursor-B-ALL study 7 (PDX; short-term; <10wk) / precursor-B-ALL study 7 (early relapse; <24m)

Relative Expression (log2-ratio):2.861929
Number of Samples:5 / 22
Experimental precursor-B-ALL study 7 (PDX; short-term; <10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia (B-ALL) generated in NOD/SCID mice with time to manifestation of leukemia (TTL) less than 10 weeks (short-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene,;remision at day 33; non-high risk group; early relapse group (relapse within 24 months from diagnosis).
Control precursor-B-ALL study 7 (early relapse; <24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse within 24 months after diagnosis (early relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)

Relative Expression (log2-ratio):-2.7444553
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).

endothelin 1 study 1 / normal iPSC-derived cardiomyocyte sample

Relative Expression (log2-ratio):2.6362991
Number of Samples:3 / 3
Experimental endothelin 1 study 1
Human induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs) treated with 10nM endothelin 1 (ET-1) for 18hours. These cardiomyocytes are a highly pure ventricular population established as having functional properties similar to adult human cardiomyocytes. All iPSC-CMs were obtained from one single batch of cells. After two days of recovery, the cells were cultured in William’s E medium supplemented with Cocktail B (1:25) from the Hepatocyte Maintenance Supplement Pack. After an additional 11 days of recovery, cells were stimulated for 18 h with 10nM ET-1. ET-1 is a potent vasoconstrictor and a well established modulator of cardiac hypertrophy in humans. ATC code:---
Control normal iPSC-derived cardiomyocyte sample
Human induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs). These cardiomyocytes are a highly pure ventricular population established as having functional properties similar to adult human cardiomyocytes. All iPSC-CMs were obtained from one single batch of cells. The cells were cultured in William’s E medium supplemented with Cocktail B (1:25) from the Hepatocyte Maintenance Supplement Pack.

HT29-R / HT-29

Relative Expression (log2-ratio):2.6176758
Number of Samples:3 / 3
Experimental HT29-R
Human primary cancer cell line derived from the colon of a patient with carcinoma. HT29 resistant to 10-5 M Methotrexate (MTX). This corresponds to a 1000-fold increase in resistance with respect to the sensitive HT29 cells, and was obtained upon incubation with stepwise concentrations of MTX. Parental cell line:: HT-29 Synonyms:HT29R Cellosaurus code:
Control HT-29
Human primary cancer cell line derived from the colon of a female patient with adenocarcinoma. Synonyms:HT 29; HT29 Cellosaurus code:

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-2.5915747
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.